RCT | Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to TNFα inhibitors 19 Jan, 2023 | 14:05h | UTC Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE) – The Lancet Related Study: Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL) – The Lancet